ResearcherChonnam National UniversityActive in the last 2 years
Chang‐Hwan Park
Matched on ORCID iD 0000-0002-2995-8779; OpenAlex author ID A5027819516, A5096164946. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 18
2021: 2 papers · 2022: none · 2023: none · 2024: 2 papers
Papers 4
- Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin leve… Co-author DOI 10.1038/s41416-023-02474-w↗
- Correction: Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum … Co-author DOI 10.1038/s41416-023-02520-7↗
- Endoscopic drainage for management of infected necrosis following EUS-TA in a patient with pancreatic cancer: A case report. Last author DOI 10.1097/md.0000000000025466↗
- The Dual Effects of Silibinin on Human Pancreatic Cells Co-author DOI 10.26420/austinjcancerclinres.2021.1092↗
Closest collaborators
The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Jae Woo Kim · 2 shared papers, 2024 · strength 0.33
- Paper Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adeno… DOI 10.1038/s41416-023-02474-w↗
- Paper Correction: Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic … DOI 10.1038/s41416-023-02520-7↗
- Eui Joo Kim · 2 shared papers, 2024 · strength 0.33
- Paper Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adeno… DOI 10.1038/s41416-023-02474-w↗
- Paper Correction: Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic … DOI 10.1038/s41416-023-02520-7↗
- Mi‐Suk Park · 2 shared papers, 2024 · strength 0.33
- Paper Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adeno… DOI 10.1038/s41416-023-02474-w↗
- Paper Correction: Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic … DOI 10.1038/s41416-023-02520-7↗
- Y. Choi · 2 shared papers, 2024 · strength 0.33
- Paper Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adeno… DOI 10.1038/s41416-023-02474-w↗
- Paper Correction: Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic … DOI 10.1038/s41416-023-02520-7↗
- Si Young Song · 2 shared papers, 2024 · strength 0.33
- Paper Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adeno… DOI 10.1038/s41416-023-02474-w↗
- Paper Correction: Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic … DOI 10.1038/s41416-023-02520-7↗
- Jung Hyun Jo · 2 shared papers, 2024 · strength 0.33
- Paper Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adeno… DOI 10.1038/s41416-023-02474-w↗
- Paper Correction: Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic … DOI 10.1038/s41416-023-02520-7↗
- Hyungsik Roger Moon · 2 shared papers, 2024 · strength 0.33
- Paper Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adeno… DOI 10.1038/s41416-023-02474-w↗
- Paper Correction: Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic … DOI 10.1038/s41416-023-02520-7↗
- Dong Uk Kim · 2 shared papers, 2024 · strength 0.33
- Paper Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adeno… DOI 10.1038/s41416-023-02474-w↗
- Paper Correction: Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic … DOI 10.1038/s41416-023-02520-7↗
- Seung Ok Lee · 2 shared papers, 2024 · strength 0.33
- Paper Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adeno… DOI 10.1038/s41416-023-02474-w↗
- Paper Correction: Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic … DOI 10.1038/s41416-023-02520-7↗
- Ho Gak Kim · 2 shared papers, 2024 · strength 0.33
- Paper Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adeno… DOI 10.1038/s41416-023-02474-w↗
- Paper Correction: Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic … DOI 10.1038/s41416-023-02520-7↗
- Woo Jin Lee · 2 shared papers, 2024 · strength 0.33
- Paper Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adeno… DOI 10.1038/s41416-023-02474-w↗
- Paper Correction: Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic … DOI 10.1038/s41416-023-02520-7↗
- Yong‐Tae Kim · 2 shared papers, 2024 · strength 0.33
- Paper Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adeno… DOI 10.1038/s41416-023-02474-w↗
- Paper Correction: Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic … DOI 10.1038/s41416-023-02520-7↗
- Eunae Cho · 1 shared paper, 2021 · strength 0.22
- Young Jung Kim · 1 shared paper, 2021 · strength 0.22
- Kwang Hyuck Lee · 1 shared paper, 2024 · strength 0.16
- Kwang Hyuck Lee · 1 shared paper, 2024 · strength 0.16
- Chang Hwan P · 1 shared paper, 2021 · strength 0.13
- L Su-Mi · 1 shared paper, 2021 · strength 0.13
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.